

Relation between duration of smoking cessation and bronchial inflammation in COPD

Thérèse S. Lapperre¹, Dirkje S. Postma⁴, Margot M.E. Gosman⁴, Jiska B. Snoeck-Stroband², Nick H.T. ten Hacken⁴, Pieter S. Hiemstra¹, Wim Timens⁵, Peter J. Sterk¹, Thais Mauad^{1,3} and the GLUCOLD Study Group⁶

Depts. of ¹Pulmonology, ²General Practice, Leiden University Medical Centre, Leiden, The Netherlands; ³Dept. of Pathology, University of Sao Paulo, Sao Paulo, Brazil; Depts. of ⁴Pulmonology and ⁵Pathology, Groningen University Medical Centre, Groningen, The Netherlands; and ⁶The GLUCOLD Study Group: Groningen Leiden Universities and Corticosteroids in Obstructive Lung Disease, a full list of members is listed at the back.

Correspondence:

Thérèse S. Lapperre, MD
Lung Function Lab, C2-P, Department of Pulmonology
Leiden University Medical Centre (LUMC)
Albinusdreef 2, P.O. Box 9600
2300 RC Leiden, The Netherlands
Phone: +31 71 5263261
Fax: +31 71 5154691
Email: t.s.lapperre@lumc.nl

Running Title: Smoking cessation and bronchial inflammation in COPD

Word count: 3221

Keywords: bronchoscopy, biopsy, plasma cells, T-lymphocytes, chronic obstructive pulmonary disease

ABSTRACT

Background: Chronic obstructive pulmonary disease (COPD) is associated with airway inflammation. Although smoking cessation improves symptoms and lung function decline in COPD, it is unknown whether bronchial inflammation in patients with established COPD varies with the duration of smoking cessation.

Methods: 114 COPD patients were studied cross-sectionally: 99 males, age 62 ± 8 years, median 42 (IQR: 31-55) pack-years, no inhaled or oral corticosteroids, all current or ex-smokers (n=42, quit >1 month, median cessation duration 3.5 years), postbronchodilator FEV₁ $63\pm 9\%$ predicted, FEV₁/FVC $48\pm 9\%$. Subepithelial T-lymphocyte (CD3, CD4, CD8), neutrophil, macrophage, eosinophil, mast cell, and plasma cell numbers were measured in bronchial biopsies (median [IQR] /0.1 mm²), using fully automated image analysis.

Results: Ex-smokers with COPD had higher CD3⁺, CD4⁺, and plasma cell numbers than current smokers with COPD (149 [88-225] vs. 108 [61-164], $p=0.036$; 58 [32-90] vs. 40 [25-66], $p=0.023$; 9.0 [5.5-20] vs. 7.5 [3.1-14], $p=0.044$, respectively), but no difference in other inflammatory cells. Short-term ex-smokers (<3.5 years) had higher CD4⁺ and CD8⁺ cell numbers than current smokers ($p=0.017$, $p=0.023$; respectively). Conversely, long-term ex-smokers (quit ≥ 3.5 years) had lower CD8⁺ cell numbers than short-term ex-smokers ($p=0.009$), lower CD8/CD3 ratios than both current smokers and short-term ex-smokers ($p=0.012$, $p=0.003$; respectively), and higher plasma cell numbers than current smokers ($p=0.003$).

Conclusions: With longer duration of smoking cessation CD8 cell numbers decrease and plasma cell numbers increase. This indicates that bronchial T-lymphocyte and plasma cell counts, but not other inflammatory cells, are related to duration of smoking cessation in patients with COPD.

Word count: 247

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation and abnormal inflammatory responses in the airways.[1] Persistent smoking-induced inflammation is thought to play an important role in the pathogenesis of COPD. It is characterised by influx of neutrophils into the airway lumen, and elevated macrophage and T-lymphocyte numbers in the airway wall.[2][3] Particularly, bronchial CD8⁺ T-lymphocytes appear to be associated with the severity of the disease.[3][4] Moreover, sputum CD8⁺ cells of COPD patients have elevated cytotoxic activity[5], which may contribute to the tissue damage occurring in these patients. Recently, it was demonstrated that B cell numbers in the small airways of COPD patients are also increased.[3] Plasma cells (terminally differentiated effector B cells) are the cellular source of mucosal immunoglobulin production and consequently play a central role in host defence against infection. However, there is limited data on their role in COPD, and their presence in the lung has not been investigated in relation to smoking status.

Smoking cessation is the only intervention able to reduce COPD progression.[6] Moreover, patients who quit smoking experienced less respiratory symptoms and hyperresponsiveness as compared to those who continued smoking.[7][8] The largest improvements in lung function and symptoms occurred within the first year after cessation. It is yet unclear whether these beneficial effects are accompanied by reversal of smoking-induced pathology.

At present, there is insufficient evidence that smoking cessation reduces inflammation in COPD. There are few cross-sectional studies comparing smokers and ex-smokers regarding bronchial inflammation in heterogeneous and relatively small groups of patients without an established diagnosis of COPD.[9] Most previous studies were performed in patients with chronic bronchitis.[10][11] In patients with symptoms of chronic cough and expectoration, ex-smokers tended to have lower mast cell numbers in the lamina propria than current smokers[10], whereas the number of neutrophils, macrophages, eosinophils, and lymphocytes in bronchial biopsies have been reported to be similar.[11] Most studies did not take duration of smoking cessation into account when comparing current and ex-smokers. However, it has been shown that this may influence the inflammatory response in small airways.[12] These available studies may not be representative for COPD, since relatively low numbers of patients with airflow limitation were included. Therefore, it remains to be investigated whether bronchial inflammation varies with current smoking status and the duration of smoking cessation in patients with an established diagnosis of COPD.

In the current study, we postulated that bronchial inflammation in patients with established COPD differs between active smokers and patients who stopped smoking, and that such difference is influenced by the duration of smoking cessation. We therefore investigated the number of inflammatory cells (e.g. neutrophils, macrophages, eosinophils, mast cells, T-lymphocytes, plasma cells, and granzyme B⁺ cells as a marker of activated cytotoxic cells) in bronchial biopsies of current and ex-smokers with COPD in a large cross-sectional study.

METHODS

Subjects

Hundred fourteen patients with COPD, participating in the GLUCOLD study (Groningen Leiden Universities and Corticosteroids in Obstructive Lung Disease), were included in this study. Patient characteristics and methods have been described in detail previously.[13] In short, all patients had irreversible airflow limitation compatible with GOLD stages II and III [postbronchodilator FEV₁ and FEV₁/IVC <90% *confidence interval* (CI) of the predicted value, FEV₁ ≥1.3 liter and >20% predicted] and at least one of the following symptoms: chronic cough, chronic sputum production, or dyspnea on exertion. Patients with a history of asthma, alpha-1 antitrypsin deficiency, or other active lung disease were not permitted to the study. The study subjects did not use a course of oral steroids during the last three months, and did not have maintenance treatment with inhaled or oral steroids during the last six months. Patients were allowed to use short-acting bronchodilators, and were in clinical stable condition. They were current or ex-smokers (quit smoking for at least one month) with at least 10 pack-years of smoking. A validated questionnaire was used to assess the smoking history.[14] Those who had quit were asked at what age they stopped in order to calculate the duration of smoking cessation (years). All patients gave their written informed consent.

Design and Lung function

The study had a cross-sectional design and consisted of four visits. Spirometry, reversibility to salbutamol, and diffusion capacity were measured according to previously described methods in order to characterise the patients.[13]

Bronchoscopy

Fiberoptic bronchoscopy was performed using a standardised protocol according to recent recommendations.[15] Smokers were requested to refrain from smoking on the day of the bronchoscopy. Patients received pre-medication with 400 µg salbutamol p.i., 20 mg codeine p.o., and 0.5 mg atropine s.c., and local anesthesia with lidocaine (≤3 mg/kg). During the procedure 100% oxygen was delivered through a nasal canula (2 L/min) if required, while transcutaneous oxygen was monitored continuously by oximeter with a finger probe. Bronchoscopies were performed by experienced pulmonary physicians using a fiberoptic bronchoscope (18X, outer diameter 6 mm, Pentax Optical Co., Japan) and pairs of cup forceps (Reda, Tuttlingen, Germany). Six macroscopically adequate bronchial biopsy specimens were randomly taken from (sub) segmental carinae in the right or left lower lobe (left and right was alternated per patient, all biopsies from one lung).

Biopsy processing and staining

Four biopsies were immediately fixed in 4% neutral buffered formalin for 24 hours, then processed and embedded in paraffin, and two were immediately snap frozen and stored at –80°C. Paraffin-embedded biopsies were cut in 4 µm thick sections and haematoxylin/eosin staining was used for evaluation and selection of the two morphological best biopsies per patient for analysis (without crushing artifacts, large blood clots, or only epithelial scrapings). If required, immunohistochemistry included antigen retrieval (Table 1). Specific antibodies against T lymphocytes (CD3, CD4, CD8), macrophages (CD68), neutrophil elastase (NE), mast cell tryptase (AA1), eosinophils (EG2), plasma cells (CD138), and granzyme B were used (Table 1). Besides staining the plasma cells, CD138 (syndecan-1) antibody also stains the bronchial epithelium and submucosal glands[16], but these structures were not present in the areas of subepithelial cell quantification. All stainings, except for CD3 and CD4, were performed using an automatic staining machine (Dako), in two sessions, with one section per patient in each

session. In short, the sections were incubated with an optimal dilution of the primary antibodies in 1% BSA/PBS at room temperature for 60 min. As a secondary antibody, the horseradish peroxidase conjugated anti-mouse or anti-rabbit EnVision system (DAKO, Glostrup, Denmark) was used, with NovaRED (Vector, Burlingame, CA) as the chromagen. The sections were counterstained with Mayer's hematoxylin (Klinipath, Duiven, the Netherlands). For negative controls, the first antibody was omitted from this procedure.

Analysis of bronchial biopsies

Multiple digital images per coded biopsy section were prepared using a colour camera (Basler A101fc-le) and a dedicated software program (RVC-software, Amersfoort, The Netherlands, <http://www.rvc.nl/en/index.html>). Next, these different images were united into one large image that consisted of the entire biopsy section (100 μm = 115.7 pixels). Fully automated inflammatory cell counting procedures were performed according to previously described validated methods.[17] The number of subepithelial positively staining inflammatory cells was counted within the largest possible area, of maximal 125 μm deep beneath the basement membrane, per biopsy section, and expressed as the mean number of cells / 0.1 mm^2 of the two biopsies. Because of very low numbers of granzyme B⁺ cells, these were analysed using a semi-quantitative score of the entire biopsy section: 0 (absent staining), 1 (1-10 positive cells), or 2 (> 10 positive cells).

Statistical analysis

Mean values and standard deviations (SD) were computed for normally distributed variables. Cell counts, and other variables that did not show a normal distribution, were logarithmically transformed (square root in case of CD8/CD3 ratio) before statistical analysis, and presented as medians with interquartile range (IQR). Normally distributed log-transformed cell counts were analysed using parametric tests. EG2 data remained skewed after log-transformation and were therefore analysed using non-parametric tests. Differences between smokers and ex-smokers were explored using Chi-square tests, 2-tailed unpaired t-tests, or Mann Whitney tests. To study the influence of duration of smoking cessation on cell counts, we compared smokers with ex-smokers who quit <3.5 years and those who quit \geq 3.5 years ago, since this was the median duration of smoking cessation, using one-way ANOVA (Kruskal-Wallis tests in case of EG2). If these were statistically significant, 2-tailed unpaired t-tests were applied for further exploration of between-group differences. Multivariate linear regression analysis was applied to adjust for significant differences in patient characteristics between the groups, such as sex, age, pack-years, and FEV₁/IVC. Univariate correlations were evaluated using Spearman and Pearson's correlation coefficient. SPSS 12.0 (SPSS Inc., Chicago, IL) software was used for statistical analysis.

RESULTS

Patient characteristics

Table 2 shows the characteristics of the 72 smoking and 42 ex-smoking patients included in the study. Patients had moderate to severe COPD, based on a postbronchodilator FEV₁ of 63.0 (8.8) % predicted, and a median smoking history of 42 pack-years. Median duration of smoking cessation in ex-smokers was 3.5 (1-10) years. Differences in patient characteristics between current and ex-smokers, and between current smokers, short-term ex-smokers (quit <3.5 years ago), and long-term ex-smokers (quit ≥3.5 years ago) are demonstrated in table 2.

Bronchial inflammatory cell counts in smokers versus ex-smokers

All 114 patients underwent bronchoscopy; from one patient (ex-smoker) none of the biopsies taken were adequate for analysis. Figure 1 shows examples of biopsy sections stained with haematoxylin/eosin, CD138, CD8, and CD4. The median analysed surface area of biopsy sections (mucosal area per patient, average of all antibodies, in which cells were counted, not corrected for shrinkage) was 0.35 (0.26-0.42) mm². Ex-smokers had higher CD3⁺, CD4⁺, and CD138⁺ cell numbers than current smokers (p=0.036, p=0.023, p=0.044; respectively), but no significant difference in other inflammatory cell counts (Table 3). When differences in sex, age, and FEV₁/IVC were taken into account in multivariate linear regression analyses, differences in CD3, CD4, and CD138 remained significant. There were very few granzyme B⁺ cells in most patients [median score: 0.5 (IQR: 0-1)], and the score was not different between current and ex-smokers with COPD.

Bronchial inflammatory cell counts and duration of smoking cessation

There were significant differences for CD4⁺, CD8⁺, CD8⁺/CD3⁺, and CD138⁺ cells between current smokers, short-term ex-smokers, and long-term ex-smokers with COPD (Table 3). Short-term ex-smokers had higher CD4⁺ and CD8⁺ cell numbers than current smokers (p=0.017, p=0.023, respectively; Table 3, Figure 2). These differences persisted after adjustment for differences in postbronchodilator FEV₁/IVC between the groups. In contrast, long-term ex-smokers had lower CD8⁺ cell numbers than short-term ex-smokers (p=0.009), lower CD8⁺/CD3⁺ ratios than both current smokers (p=0.012) and short-term ex-smokers (p=0.003), and higher plasma cell numbers than current smokers (p=0.003; Table 3, Figure 2) and a trend towards significance versus short-term ex-smokers (p=0.069). When adjusting for differences in patient characteristics between the groups, all differences remained significant, except for the difference in CD8⁺ cells between short-term and long-term quitters. On the other hand, the difference in plasma cells between short-term and long-term quitters became significant when adjusting for age.

Correlations between bronchial inflammation and smoking behavior

When defining current smoking as 0 years stopped, longer duration of smoking cessation was associated with higher numbers of CD3⁺ cells (r_s=0.221, p=0.019), CD4⁺ cells (r_s=0.194, p=0.040), CD138⁺ cells (r_s=0.217, p=0.021), and a trend with CD4/CD8 ratios (r_s=0.181, p=0.056). Excluding current smokers, longer duration of smoking cessation was associated with lower CD8/CD3 ratios (r_s=-0.395, p=0.011), and a trend with higher numbers of CD138⁺ cells (r_s=0.307, p=0.051). The number of pack-years smoked was inversely correlated with CD138⁺ cells (R=-0.295, p=0.002).

DISCUSSION

The present study aimed to determine whether the inflammatory cell profile in the bronchial mucosa is different between current smokers and ex-smokers with COPD, and whether this profile is influenced by duration of smoking cessation. Ex-smokers had higher numbers of CD3⁺, CD4⁺, and plasma cells, whereas numbers of neutrophils, macrophages, eosinophils, mast cells, and CD8⁺ cells were not different from current smokers. Interestingly, short-term smoking cessation (below the median value of our cohort, i.e. <3.5 years) was associated with higher CD4⁺ and CD8⁺ T-lymphocytes, whereas long-term smoking cessation (≥3.5 years) was associated with higher plasma cell numbers and lower CD8/CD3 ratios. These results indicate that the number of bronchial T-lymphocytes and plasma cells in patients with COPD is related to current smoking status and the duration of smoking cessation.

To our knowledge, this is the first study comparing bronchial inflammation in current and ex-smokers within a group of COPD patients, and examining the association with duration of smoking cessation. The observed higher numbers of CD3⁺ and CD4⁺ lymphocytes, and plasma cells in ex-smokers with COPD compared to current smokers with COPD is novel. Consistent with our results, one previous study also reported increased inflammation in peripheral airways of ex-smokers with mild COPD and mucus hypersecretion compared to current smokers, though the type of cells was not specified.[18] Our observation that large airway inflammation in COPD persists after smoking cessation is in line with preceding results in smaller numbers of patients with chronic bronchitis.[11] Rutgers *et al.*, also reported ongoing airway inflammation in ex-smokers with COPD when compared to healthy ex-smokers, however, in contrast to the present study, they did not include current smokers with COPD in the analysis.[19] Our results of T-lymphocytes and plasma cells being associated with duration of smoking cessation in COPD are not in line with a previous study, showing no difference in general peripheral airway inflammation between patients with COPD who quit >2 years, <2 years, and current smokers.[20] However, Lams *et al.* reported that CD8/CD3 ratios in peripheral airways are inversely associated with duration of smoking cessation in patients with and without airflow limitation.[12] Taken together, it can now be inferred that within a group of COPD patients, T-lymphocytes and plasma cell numbers are related to current smoking status and duration of smoking cessation, whereas other inflammatory cells are not.

It seems unlikely that our results are affected by methodological errors. To our knowledge, this is the largest study to date including bronchial biopsies of 114 well-characterised patients with stable COPD of GOLD stages II and III, not using inhaled or oral steroids, and without a clinical diagnosis of asthma. It needs to be emphasised that this was a cross-sectional study, and it cannot be ruled out that our ex-smoking group is a selected group of patients who quit smoking because they suffered more from smoking related symptoms, and may already have had different cell numbers before quitting. Nevertheless, in the present study ex-smokers had significantly less respiratory symptoms than current smokers, whilst having similar pack-years and duration of smoking. In addition, in our analysis we did adjust for clinical differences between the groups. We did not confirm smoking status by laboratory tests, and therefore cannot exclude that some ex-smokers were still smoking. However, this problem is comparable to those in other cross-sectional studies in this area.[10][11][19] A fully automated image analysis system was applied for cell counting in airway area sections.[17] We are aware that counting cells in a 2d manner has limitations, since it does not take into account the volume of the cell in a given sample – the smallest cells have the least chance to be counted in a single biopsy. Nevertheless, we were able to demonstrate differences in the smallest cells (LY) between the groups. There is still debate in the literature whether the theoretic basis of stereology fits well with the limitations of endobronchial biopsies.[21] Still,

most of the present data in the literature is based on counting profiles/area, what allows, although somehow limited by other methodological factors, comparison among studies. Because we observed no granzyme B⁺ cells in the majority of biopsy sections analysed (56% of all sections), and no differences in a semi-quantitative score between the groups, we did not use digital image analysis for granzyme B⁺ cell quantification, which is a more time-consuming procedure. Finally, we choose 3.5 years as a cut-off value for short-term versus long-term smoking cessation groups because this was the median duration of smoking cessation, providing equal sample sizes in both groups.

How can we interpret these data? The ongoing inflammation in ex-smokers with COPD suggests the presence of a persistent stimulus that may act independently of cigarette smoking. There are several potential mechanisms. For instance, chronic colonization of the airways with viral and/or bacterial pathogens in smokers with COPD[22], which may be responsible for the inflammatory response[23][24] and persist after smoking cessation. In agreement with this, it was observed previously that latent adenovirus could persist in ex-smokers with COPD, which is associated with amplification of inflammation.[25][26] Smoking may also trigger self-perpetuating inflammatory mechanisms by altering the balance between endogenous pro- and anti-inflammatory mechanisms, or – as recently suggested – may induce autoimmune-like phenomena.[27][28] In addition, it was recently observed that apoptosis of airway epithelial cells persists after smoking cessation in patients with COPD[29], which may induce persistence of inflammation. It has been suggested that in smokers without COPD or chronic bronchitis who stopped smoking, lung inflammation is at least partially reversible[9], whereas it persists in patients with COPD. Therefore, it is possible that the before mentioned stimuli may not persist in ex-smokers without COPD or chronic bronchitis.

The initial increase in CD4⁺ and CD8⁺ cells, and later increase in plasma cells, after smoking cessation might be explained by reversal of immunosuppression. Since both CD4 and CD8 cell numbers returned to similar levels as current smokers in long-term quitters, this reversal of immunosuppression seems transient for lymphocytes, but persistent for plasma cells. Smoking cessation may result in reversal of smoking-induced harmful effects on airway epithelial cells[30], such as a reduction in metaplastic secretory cell numbers in small airways[20][31], leading to improved lung defence mechanisms. Hence, the effector mechanisms of immunity to environmental antigens could be stimulated more efficiently in the absence of smoking, leading to a higher number of immunocompetent cells. Whereas the pro-inflammatory effects of active tobacco smoking have been extensively documented, it may also have selective anti-inflammatory effects, as has been described for acute effects of smoking.[32] Consistent with this and with our results, it was recently observed that cigarette smoke exposure reduced CD4 cell expansion following virus infection.[33] In addition, tobacco smokers have decreased serum levels of immunoglobulins IgG and IgA[33][34], suggesting that cigarette smoke modulates the humoral arm of adaptive immunity. Indeed, Soutar *et al.* described decreased numbers of IgA⁺ cells in patients with fatal chronic bronchitis, and suggested that these patients were deficient in plasma cells.[35] These effects of decreased serum immunoglobulin levels appear to be reversible after smoking cessation.[36] It is possible that smoking cessation leads to an improved capacity of producing immunoglobulins in the airway mucosa of patients with COPD, by causing an increase in plasma cell numbers. Loss of these suppressive effects with smoking cessation may also explain our findings of increased numbers of inflammatory cells in ex-smokers, and thereby ameliorating lung defence mechanisms.

The decreased CD8/CD3 ratio after quitting for ≥ 3.5 years compared to current smokers and short-term quitters, and the lower CD8⁺ cell numbers in long-term compared to short-term quitters, suggest that smoking cessation eventually may result in decreased CD8⁺ cell

numbers. Since CD8⁺ cells have been implicated in the pathogenesis of COPD, a decrease in number of these cells or their cytotoxic activity may have beneficial effects. However, our findings of very low numbers of cells that stain positive for the CD8 effector molecule granzyme B in the airways of patients with COPD, in the absence of differences between current and ex-smokers, suggest that these cells may not be cytotoxic. This may be because granzymes are involved in the pathogenesis of emphysema rather than in the conducting airways.[37] In this respect, it is interesting to note that antigen-specific CD8⁺ T-lymphocytes can persist in the lung long after clearance of a respiratory virus, and that these cells are highly activated and can be stimulated to proliferate, but do not express constitutive effector functions.[38] In line with these findings, we did observe high numbers of granzyme B positive cells in lung tissue from children with childhood bronchiolitis obliterans, a disease that is thought to result from acute viral bronchiolitis.[39] In vitro studies may provide additional information by examining more extensively the possible lack of cytotoxicity of CD8⁺ T-lymphocytes in COPD.

What could be the clinical implications of our findings? There is good evidence that smoking cessation results in a decrease in respiratory symptoms[7], a lower decline in FEV₁[6], and a reduction of airway hyperresponsiveness.[8][40] Our data suggest that T-lymphocytes and plasma cell numbers change after smoking cessation in COPD, while other inflammatory cells persist. Whether these, relatively small, changes in T-lymphocytes and plasma cell numbers contribute to the clinical benefits of smoking cessation in patients with COPD, remains to be established in longitudinal studies. The results propose that smoking cessation may result in improvement of the local humoral immunity, which may result in less respiratory infections and exacerbations, and thereby a reduced progression of COPD. However, the data also suggest that the clinical benefits of smoking cessation do not simply result from a reduction in inflammatory cells. The mechanisms causing this sustained inflammatory pattern after smoking cessation in COPD remain to be clarified.

In conclusion, the present study has shown that ex-smokers with COPD have higher numbers of bronchial CD4⁺ and plasma cells than current smokers, whereas numbers of neutrophils, macrophages, and CD8⁺ cells are not different between both groups. T-lymphocytes are higher in short-term quitters, whereas longer duration of smoking cessation is associated with lower CD8/CD3 ratios, and higher numbers of plasma cells. This suggests that changes in T-lymphocyte and plasma cell numbers may contribute to the clinical benefits of smoking cessation in COPD.

ACKNOWLEDGEMENTS

We thank the patients for their cooperation in our study.

The GLUCOLD Study Group consists of: H.F. Kauffman, D. de Reus, Dept. of Allergology; H.M. Boezen, D.F. Jansen, J. Vonk, Dept. of Epidemiology and Statistics; M.D.W. Barentsen, W. Timens, M. Zeinstra-Smit, Dept. of Pathology; A.J. Luteijn, T. van der Molen, G. ter Veen, Dept. of General Practice; M.M.E. Gosman, N.H.T. ten Hacken, H.A.M. Kerstjens, M.S. van Maaren, D.S. Postma, C.A. Veltman, A. Verbokkem, I. Verhage, H.K. Vink-Kloosters, Dept. of Pulmonology; Groningen University Medical Center, Groningen, The Netherlands. J.B. Snoeck-Stroband, H. Thiadens, Dept. of General Practice; J.K. Sont, Dept. of Medical Decision Making; I. Bajema, Dept. of Pathology; J. Gast-Strookman, P.S. Hiemstra, K. Janssen, T.S. Lapperre, K.F. Rabe, A. van Schadewijk, J. Smit-Bakker, P.J. Sterk, J. Stolk, A.C.J.A. Tiré, H. van der Veen, M.M.E. Wijffels and L.N.A. Willems, Dept. of Pulmonology; Leiden University Medical Center, Leiden, The Netherlands; T. Mauad, University of Sao Paulo, Sao Paulo, Brazil.

SOURCES OF FINANCIAL SUPPORT

The study was supported by: Netherlands Organization for Scientific Research (NWO), the Netherlands Asthma Foundation (NAF), GlaxoSmithKline (NL), Leiden University Medical Center (LUMC), and Groningen University Medical Center (GUMC).

ETHICS APPROVAL

The medical ethics committees of the Leiden University Medical Center and the Groningen University Medical Center approved the study.

COMPETING INTEREST STATEMENT

PS and PH have received, as members of the department of Pulmonology of the LUMC, a grant from GSK (UK and NL) as part of the sponsorship of this GLUCOLD study. The other authors declare no competing interests.

COPYRIGHT

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in THORAX and any other BMJ PGL products and sublicenses such use and exploit all subsidiary rights, as set out in our license (<http://thorax.bmjournals.com/misc/ifora/licenceform.shtml>).

FIGURE LEGENDS

Figure 1.

(A) Bronchial biopsy section of a patient with COPD stained with haematoxylin/eosin, showing goblet cell hyperplasia of the bronchial epithelium (*arrow*), fibrosis (*FI*), and scattered inflammatory cells in the submucosa. (B) Plasma cell staining (CD138). The epithelial layer also stained positive, however for the analysis only the subepithelial layer was taken into account. (C) CD8⁺ T-lymphocyte staining. (D) CD4⁺ T-lymphocytes staining, also showing squamous cell metaplasia of the epithelium (*arrow*). Scale bars: (A) 100 μm , (B, C and D) 20 μm .

Figure 2.

Difference in CD4, CD8, CD8/CD3, and CD138 cell counts in the lamina propria of smokers (S), ex-smokers who quit <3.5 years ago (<3.5 ex-S), and who quit ≥ 3.5 years ago (≥ 3.5 ex-S) with COPD. Data are presented as box plots (median, IQR, range) of the number of cells /0.1 mm² tissue examined or ratios. * p<0.05: 2-tailed unpaired t-tests of log transformed data (square root in case of CD8/CD3).

REFERENCES

- 1 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Available at: www.goldcopd.com . 2004.
- 2 Saetta M, Turato G, Maestrelli P et al. Cellular and structural bases of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;163(6):1304-1309.
- 3 Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* 2004;350(26):2645-2653.
- 4 O'Shaughnessy TC, Ansari TW, Barnes NC et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8⁺ T lymphocytes with FEV₁. *Am J Respir Crit Care Med* 1997;155(3):852-857.
- 5 Chrysofakis G, Tzanakis N, Kyriakoy D et al. Perforin expression and cytotoxic activity of sputum CD8⁺ lymphocytes in patients with COPD. *Chest* 2004;125(1):71-76.
- 6 Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. *JAMA* 1994;272(19):1497-1505.
- 7 Kanner RE, Connett JE, Williams DE et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. *Am J Med* 1999;106(4):410-416.
- 8 Wise RA, Kanner RE, Lindgren P et al. The Effect of Smoking Intervention and an Inhaled Bronchodilator on Airways Reactivity in COPD: The Lung Health Study. *Chest* 2003;124(2):449-458.
- 9 Willemse BW, Postma DS, Timens W et al. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. *Eur Respir J* 2004;23(3):464-476.
- 10 Pesci A, Rossi GA, Bertorelli G et al. Mast cells in the airway lumen and bronchial mucosa of patients with chronic bronchitis. *Am J Respir Crit Care Med* 1994;149(5):1311-1316.
- 11 Turato G, Di Stefano A, Maestrelli P et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. *Am J Respir Crit Care Med* 1995;152(4 Pt 1):1262-1267.
- 12 Lams BE, Sousa AR, Rees PJ et al. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;158(5 Pt 1):1518-1523.
- 13 Lapperre TS, Snoeck-Stroband JB, Gosman MM et al. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004;170:499-504.

- 14 Pauwels RA, Löfdahl C-G, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. *N Engl J Med* 1999;340:1948-1953.
- 15 Jeffery P, Holgate S, Wenzel S. Methods for the assessment of endobronchial biopsies in clinical research: application to studies of pathogenesis and the effects of treatment. *Am J Respir Crit Care Med* 2003;168(6 Pt 2):S1-17.
- 16 KleinJan A, Vinke JG, Severijnen LW et al. Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients. *Eur Respir J* 2000;15(3):491-497.
- 17 Sont JK, de Boer WI, van Schadewijk WA et al. Fully automated assessment of inflammatory cell counts and cytokine expression in bronchial tissue. *Am J Respir Crit Care Med* 2003;167(11):1496-1503.
- 18 Mullen JB, Wright JL, Wiggs BR et al. Structure of central airways in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function. *Thorax* 1987;42(11):843-848.
- 19 Rutgers SR, Postma DS, ten Hacken NH et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. *Thorax* 2000;55(1):12-18.
- 20 Wright JL, Lawson LM, Pare PD et al. Morphology of peripheral airways in current smokers and ex-smokers. *Am Rev Respir Dis* 1983;127(4):474-477.
- 21 Fehrenbach H. Design-based counting. *Am J Respir Crit Care Med* 2004;169(10):1170-1171.
- 22 Zalacain R, Sobradillo V, Amilibia J et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. *Eur Respir J* 1999;13(2):343-348.
- 23 Soler N, Ewig S, Torres A et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. *Eur Respir J* 1999;14(5):1015-1022.
- 24 Hill AT, Campbell EJ, Hill SL et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. *Am J Med* 2000;109(4):288-295.
- 25 Retamales I, Elliott WM, Meshi B et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. *Am J Respir Crit Care Med* 2001;164(3):469-473.
- 26 Shapiro SD. End-stage chronic obstructive pulmonary disease: the cigarette is burned out but inflammation rages on. *Am J Respir Crit Care Med* 2001;164(3):339-340.
- 27 Agusti A, MacNee W, Donaldson K et al. Hypothesis: does COPD have an autoimmune component? *Thorax* 2003;58(10):832-834.
- 28 Cosio MG. Autoimmunity, T-cells and STAT-4 in the pathogenesis of chronic obstructive pulmonary disease. *Eur Respir J* 2004;24(1):3-5.

- 29 Hodge S, Hodge G, Holmes M et al. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. *Eur Respir J* 2005;25(3):447-454.
- 30 Dye JA, Adler KB. Effects of cigarette smoke on epithelial cells of the respiratory tract. *Thorax* 1994;49(8):825-834.
- 31 Wright JL, Churg A. Smoking cessation decreases the number of metaplastic secretory cells in the small airways of the Guinea pig. *Inhal Toxicol* 2002;14(11):1153-1159.
- 32 van der Vaart H, Postma DS, Timens W et al. Acute effects of cigarette smoke on inflammation and oxidative stress: a review. *Thorax* 2004;59(8):713-721.
- 33 Robbins CS, Dawe DE, Goncharova SI et al. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. *Am J Respir Cell Mol Biol* 2004;30(2):202-211.
- 34 Gyllen P, Andersson BA, Qvarfordt I. Smokeless tobacco or nicotine replacement therapy has no effect on serum immunoglobulin levels. *Respir Med* 2004;98(2):108-114.
- 35 Soutar CA. Distribution of plasma cells and other cells containing immunoglobulin in the respiratory tract in chronic bronchitis. *Thorax* 1977;32(4):387-396.
- 36 Mili F, Flanders WD, Boring JR et al. The associations of race, cigarette smoking, and smoking cessation to measures of the immune system in middle-aged men. *Clin Immunol Immunopathol* 1991;59(2):187-200.
- 37 Möller GM, Vernooy JH, van Suylen RJ et al. Increased expression of granzyme A in type II pneumocytes and lymphocytes of patients with severe COPD. *Am J Respir Crit Care Med* 167[7], A72. 2003.
- 38 Hogan RJ, Usherwood EJ, Zhong W et al. Activated antigen-specific CD8⁺ T cells persist in the lungs following recovery from respiratory virus infections. *J Immunol* 2001;166(3):1813-1822.
- 39 Mauad T, van Schadewijk A, Schrupf J et al. Lymphocytic inflammation in childhood bronchiolitis obliterans. *Pediatr Pulmonol* 2004;38(3):233-239.
- 40 Willemse BW, ten Hacken NH, Rutgers B et al. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. *Eur Respir J* 2004;24(3):391-396.

Table 1. Antibodies used for immunohistochemistry

Ab	Pretreatment	Species	Dilution	Clone	Origin*
CD3 (lymphocyte)	citrate	rabbit	1:500	polyclonal	DAKO
CD4 (T-helper)	citrate	mouse	1:300	CD4-368	Novocastra
CD8 (T-cytotoxic)	citrate	mouse	1:50	CD8-144B	DAKO
Neutrophil elastase (neutrophil)	protease	mouse	1:3200	NP57	DAKO
CD68 (macrophage)	citrate	mouse	1:3000	KP1	DAKO
Tryptase (mast cell)	citrate	mouse	1:16000	AA1	DAKO
EG2 (eosinophil)	trypsin	mouse	1:150	EG-2	Pharmacia
CD138 (plasma cell)	EDTA	mouse	1:6400	B-B4	IQ products
Granzyme B	citrate	mouse	1:200	CLB-GB7	CLB/Sanquin

Footnote table 1.

* Dako, Glostrup, Denmark; Novocastra, Newcastle upon Tyne, United Kingdom; Pharmacia Diagnostics, Uppsala, Sweden; IQ products, Groningen, The Netherlands; CLB/Sanquin, Amsterdam, The Netherlands

Table 2. Patient Characteristics of current smokers and ex-smokers groups with COPD

	COPD Current smokers	COPD Ex-smokers, combined group	COPD Ex-smokers, quit <3.5 yrs	COPD Ex-smokers, quit ≥3.5 yrs
<i>General</i>				
Sex (M/F, n)	59 / 13	40 / 2 *	20 / 1	20 / 1
Age (yrs)	60 ± 8	64 ± 7 *	61 ± 8	67 ± 4 *†
Pack-years (yrs)	43 (32-56)	37 (28-53)	45 (29-65)	35 (26-41) *
Duration of smoking cessation (yrs)	-	3.5 (1-10)	1.0 (1.0-2.0)	10 (6.5-14.5)
Smoking duration (yrs)	44 ± 8	41 ± 10	43 ± 11	39 ± 8
Chronic bronchitis (%)	55.6	31.0 *	23.8 *	38.1
<i>Lung Function</i>				
Postbronchodilator FEV ₁ (%pred)	63.3 ± 8.3	62.5 ± 9.6	62.6 ± 10	62.5 ± 9.4
Postbronchodilator FEV ₁ /IVC (%)	49.5 ± 8.5	46.0 ± 8.3 *	45.3 ± 8.6 *	46.7 ± 8.1
ΔFEV ₁ (%pred)	6.9 ± 5.2	6.8 ± 4.5	6.9 ± 3.9	6.8 ± 5.1
K _{CO} (%pred)	73.3 ± 25.1	80.4 ± 25.9	75.3 ± 24.9	85.7 ± 26.5 *

Footnote table 2.

Data are presented as mean ± standard deviation or median (IQR: 25th - 75th percentile), ex-smokers divided in two groups based on median duration of smoking cessation (3.5 years). FEV₁= Forced expiratory volume in one second, IVC= Inspiratory vital capacity, ΔFEV₁= Reversibility to salbutamol (change in FEV₁ as percentage of predicted), K_{CO}= Diffusing capacity for carbon monoxide per liter alveolar volume, pred= predicted.

* p<0.05: significant difference from COPD current smokers [Chi-square tests for sex differences, 2-tailed unpaired t-tests for other (log-transformed) data];

† p<0.05: significant difference from COPD ex-smokers who quit <3.5 yrs (2-tailed unpaired t-tests).

Table 3. Bronchial inflammatory cell counts of current smokers and ex-smokers groups with COPD

Cell marker	COPD Current smokers	COPD Ex-smokers, combined group	COPD Ex-smokers, quit <3.5 yrs	COPD Ex-smokers, quit ≥3.5 yrs	p value ‡
CD3	108 (61-164)	149 (88-225) *	137 (93-229)	170 (62-221)	0.097
CD4	40 (25-66)	58 (32-90) *	64 (30-111) *	54 (32-75)	0.045
CD8	20 (11-37)	24 (8.8-41)	34 (18-54) *	16 (7.8-32) †	0.023
CD4/CD8	2.0 (1.1-3.7)	2.7 (1.3-5.0)	2.1 (1.2-3.3)	3.1 (1.8-6.4)	0.065
CD4/CD3	0.4 (0.3-0.6)	0.4 (0.3-0.8)	0.5 (0.3-0.8)	0.4 (0.3-0.6)	0.680
CD8/CD3	0.2 (0.1-0.3)	0.2 (0.1-0.3)	0.3 (0.2-0.4)	0.1 (0.1-0.2) *†	0.008
NE (neutrophils)	4.0 (2.0-7.8)	4.5 (2.0-9.0)	5.0 (2.6-9.0)	4.0 (1.8-9.8)	0.289
CD68 (macrophages)	8.5 (4.1-12)	11 (5.8-18)	11 (5.8-17)	8.5 (5.8-18)	0.124
EG2 (eosinophils)	1.3 (0.5-3.0)	2.0 (0.5-5.5)	1.5 (0.5-2.8)	3.5 (0.5-11)	0.183
AA1 (mast cells)	28 (20-34)	26 (18-35)	28 (22-36)	24 (14-33)	0.303
CD138 (plasma cells)	7.5 (3.1-14)	9.0 (5.5-20)*	7.8 (4.0-11)	12 (7.8-24) *	0.013




Footnote table 3.

Data are presented as median cell number /0.1 mm² (IQR), ex-smokers divided in two groups based on median duration of smoking cessation (3.5 years).

* p<0.05: significant difference from COPD current smokers (2-tailed unpaired t-tests of log-transformed data, square root in case of CD8/CD3);

† p<0.05: significant difference from COPD ex-smokers who quit < 3.5 yrs (2-tailed unpaired t-tests of log-transformed data, square root in case of CD8/CD3);

‡ p value from one-way ANOVA (Kruskal-Wallis test in case of EG2) of log-transformed data (square root in case of CD8/CD3) between current smokers, < and ≥3.5 yrs ex-smokers with COPD.

A**B****C****D**